Design, manufacture and initial tests of a drug-eluting coronary stent

被引:0
|
作者
Abundes-Velasco, Arturo [1 ]
Padilla-Ibarra, Jorge [2 ]
Jimenez-Rodriguez, Gian M. [2 ]
Farjat-Pasos, Julio, I [2 ]
Arias-Sanchez, Eduardo A. [2 ]
Damas-de los Santos, Felix [2 ]
Martinez-Rios, Marco A. [2 ]
Molina-Mendez, Francisco J. [3 ]
Sanchez-Perez, Tomas E. [1 ]
Arai-Ito, Marco M. [1 ]
Aceves-Diaz Gonzalez, Sebastian [1 ]
Rodriguez-Parra, David A. [1 ]
Aranda-Fraustro, Alberto [4 ]
Masso-Rojas, Felipe A. [5 ]
Galaz-Mendez, Ramses [6 ]
Pena-Duque, Marco A. [1 ]
机构
[1] Inst Nacl Cardiol Ignacio Chavez Desarrollo & Inn, Ciudad De Mexico, Mexico
[2] Inst Nacl Cardiol Ignacio Chavez, Cardiol Intervencionista, Ciudad De Mexico, Mexico
[3] Inst Nacl Cardiol Ignacio Chavez, Anestesiol Cardiovasc, Ciudad De Mexico, Mexico
[4] Inst Nacl Cardiol Ignacio Chavez, Patol, Ciudad De Mexico, Mexico
[5] Inst Nacl Cardiol Ignacio Chavez, Fisiol, Ciudad De Mexico, Mexico
[6] Inst Tecnol & Estudios Super Monterrey, Ingn Biomed, Campus Ciudad Mexico, Ciudad De Mexico, Mexico
来源
GACETA MEDICA DE MEXICO | 2020年 / 156卷 / 04期
关键词
Drug-eluting coronary stent; Sirolimus; Coronary stent; IMPLANTATION; GUIDELINES; EFFICACY; SAFETY;
D O I
10.24875/GMM.20005675
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: A drug-eluting coronary stent is being developed at the National Institute of Cardiology of Mexico for the treatment of ischemic heart disease. Objective: To establish the best animal model for the tests, to show the advances in the drug-eluting stent prototype, to assess two drugs' antiproliferative activity and histological results. Method: Smooth muscle cell culture tests were performed in order to assess sirolimus and paclitaxel antiproliferative properties. The drugs were encapsulated inside the polymeric matrix of the stents. Rabbits and pigs were used as animal models. Results: Sirolimus and paclitaxel showed an inhibitory effect, which was higher for the latter. Infrared spectroscopy and light and optical microscopy showed that the drug/polymer layer properly adhered to the stent. At a four-week follow-up, both animal models showed satisfactory clinical evolution and adequate histological response, although the porcine model was shown to be more suitable for future protocols. Conclusions: Preliminary tests of the drug-eluting stent provided bases for the development of a study protocol with an adequate number of pigs and with clinical angiographic and histopathological three-month follow-up.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 50 条
  • [31] Comparisons of Drug-Eluting Balloon versus Drug-Eluting Stent in the Treatment of Young Patients with Acute Myocardial Infarction
    Yang, Yi-Xing
    He, Kui-Zheng
    Li, Jiang-Yuan
    Fu, Yuan
    Li, Chuang
    Liu, Xin-Ming
    Wang, Hong-Jiang
    Chen, Mu-Lei
    Su, Pi-Xiong
    Xu, Li
    Wang, Le-Feng
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (01)
  • [32] Late stent thrombosis, endothelialisation and drug-eluting stents
    Ertas, G.
    van Beusekom, H. M.
    van der Giessen, W. J.
    NETHERLANDS HEART JOURNAL, 2009, 17 (04) : 177 - 180
  • [33] Results of drug-eluting stent in significant restenosis of the hemodialysis access: An initial study
    Hongsakul, Keerati
    Akkakrisee, Surasit
    Bannangkoon, Kittipitch
    Boonsrirat, Ussanee
    Premprabha, Dhanakom
    Juntarapatin, Pong
    SEMINARS IN DIALYSIS, 2022, 35 (02) : 165 - 170
  • [34] Clinical Outcome of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation for the Treatment of Coronary Drug-Eluting Stent In-Stent Chronic Total Occlusion
    Zhang, Yuchao
    Wu, Zheng
    Wang, Shaoping
    Liu, Tong
    Liu, Jinghua
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (06) : 1155 - 1166
  • [35] Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry
    Lee, Joo Myung
    Kang, Jeehoon
    Lee, Euijae
    Hwang, Doyeon
    Rhee, Tae-Min
    Park, Jonghanne
    Kim, Hack-Lyoung
    Lee, Sang Eun
    Han, Jung-Kyu
    Yang, Han-Mo
    Park, Kyung Woo
    Na, Sang-Hoon
    Kang, Hyun-Jae
    Koo, Bon-Kwon
    Kim, Hyo-Soo
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (20) : 2097 - 2109
  • [36] Downstream coronary effects of drug-eluting stents
    Krasuski, Richard A.
    Cater, George M.
    Devendra, Ganesh P.
    Wolski, Kathy
    Shishehbor, Mehdi H.
    Nissen, Steven E.
    Oberti, Carlos
    Ellis, Stephen G.
    AMERICAN HEART JOURNAL, 2011, 162 (04) : 764 - U225
  • [37] Initial impact of drug-eluting Stents on coronary artery bypass grafting
    Ishikawa, Susumu
    Kawasaki, Akio
    Neya, Kazuo
    Wada, Shinichi
    Kito, Hiroaki
    Ueda, Keisuke
    INTERNATIONAL HEART JOURNAL, 2007, 48 (04) : 455 - 461
  • [38] Very late coronary aneurysm formation with subsequent stent thrombosis secondary to drug-eluting stent
    Akin, Ibrahim
    Kische, Stephan
    Rehders, Tim C.
    Schneider, Henrik
    Turan, Goekmen R.
    Kleinfeldt, Tilo
    Ortak, Jasmin
    Ince, Hueseyin
    Nienaber, Christoph A.
    CHINESE MEDICAL JOURNAL, 2011, 124 (20) : 3427 - 3429
  • [39] Everolimus drug-eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry
    Diaz Fernandez, Jose Francisco
    Camacho Freire, Santiago Jesus
    Fernandez Guerrero, Juan Carlos
    Delarche, Nicolas
    Bretelle, Christophe
    Zueco Gil, Javier
    Lopez Palop, Ramon
    Garcia del Blanco, Bruno
    Mainar Tello, Vicente
    Albert, Franck
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2018, 92 (07) : E493 - E501
  • [40] eComment: Is the pathology different between drug-eluting stent and bare stent related coronary aneurysms?
    Arslan, Yucesin
    Hasdemir, Hakan
    Kehlibar, Tamer
    Yilmaz, Mehmet
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2011, 12 (04) : 638 - 638